These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 20712575)

  • 1. Interleukin 2 in cancer therapy.
    Antony GK; Dudek AZ
    Curr Med Chem; 2010; 17(29):3297-302. PubMed ID: 20712575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard.
    Dutcher JP
    Oncology (Williston Park); 2011 Apr; 25(5):427-8. PubMed ID: 21710841
    [No Abstract]   [Full Text] [Related]  

  • 3. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
    Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
    Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of recent findings involving interleukin-2-based cancer therapy.
    Eklund JW; Kuzel TM
    Curr Opin Oncol; 2004 Nov; 16(6):542-6. PubMed ID: 15627015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.
    Kirkwood JM; Tarhini AA
    J Clin Oncol; 2009 Jun; 27(16):2583-5. PubMed ID: 19364958
    [No Abstract]   [Full Text] [Related]  

  • 6. Interleukin-2 in the treatment of renal cell carcinoma and malignant melanoma.
    Eklund JW; Kuzel TM
    Cancer Treat Res; 2005; 126():263-87. PubMed ID: 16209070
    [No Abstract]   [Full Text] [Related]  

  • 7. Is IL-2 still indicated for melanoma and RCC? What a question to ask!
    Hamid O
    Oncology (Williston Park); 2013 Jul; 27(7):695, 701. PubMed ID: 23977765
    [No Abstract]   [Full Text] [Related]  

  • 8. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy.
    Capuron L; Ravaud A; Miller AH; Dantzer R
    Brain Behav Immun; 2004 May; 18(3):205-13. PubMed ID: 15050647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weighing the evidence for immune therapy and targeted therapy in renal cancer and melanoma.
    Dorff TB; Wong MK
    Oncology (Williston Park); 2013 Jul; 27(7):691-2, 694. PubMed ID: 23977764
    [No Abstract]   [Full Text] [Related]  

  • 10. Peripheral nerve entrapment: an unusual adverse event with high-dose interleukin-2 therapy.
    Sikora SS; Samsonov ME; Dookeran KA; Edington H; Lotze MT
    Ann Oncol; 1996 Jul; 7(5):535-6. PubMed ID: 8839913
    [No Abstract]   [Full Text] [Related]  

  • 11. High-dose interleukin-2 in metastatic disease: renal cell carcinoma and melanoma.
    Dutcher J
    Oncology (Williston Park); 2002 Nov; 16(11 Suppl 13):3. PubMed ID: 12469933
    [No Abstract]   [Full Text] [Related]  

  • 12. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma.
    Du Bois JS; Trehu EG; Mier JW; Shapiro L; Epstein M; Klempner M; Dinarello C; Kappler K; Ronayne L; Rand W; Atkins MB
    J Clin Oncol; 1997 Mar; 15(3):1052-62. PubMed ID: 9060545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines.
    Dutcher J; Atkins MB; Margolin K; Weiss G; Clark J; Sosman J; Logan T; Aronson F; Mier J;
    Med Oncol; 2001; 18(3):209-19. PubMed ID: 11917945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-2: clinical applications.
    Atkins MB
    Semin Oncol; 2002 Jun; 29(3 Suppl 7):12-7. PubMed ID: 12068383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-2.
    Med Lett Drugs Ther; 1990 Sep; 32(826):85-6. PubMed ID: 2202892
    [No Abstract]   [Full Text] [Related]  

  • 17. CD4+CD25highFOXP3+ regulatory T cells in peripheral blood are primarily of effector memory phenotype.
    Beyer M; Schultze JL
    J Clin Oncol; 2007 Jun; 25(18):2628-30; author reply 2630-2. PubMed ID: 17577047
    [No Abstract]   [Full Text] [Related]  

  • 18. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma.
    Cesana GC; DeRaffele G; Cohen S; Moroziewicz D; Mitcham J; Stoutenburg J; Cheung K; Hesdorffer C; Kim-Schulze S; Kaufman HL
    J Clin Oncol; 2006 Mar; 24(7):1169-77. PubMed ID: 16505437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose interleukin-2: is it still indicated for melanoma and RCC in an era of targeted therapies?
    Amin A; White RL
    Oncology (Williston Park); 2013 Jul; 27(7):680-91. PubMed ID: 23977763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma.
    Hughes T; Klairmont M; Broucek J; Iodice G; Basu S; Kaufman HL
    Cancer Immunol Immunother; 2015 Apr; 64(4):459-65. PubMed ID: 25603775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.